Avoro Capital Advisors LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Avoro Capital Advisors LLC reported 39 stock positions worth $7.1 billion. Its top holding was United Therapeutics (UTHR) at 13.8% of the portfolio, followed by Argenx SE - ADR (ARGX, 10.8%) and Ascendis Pharma A/S (ASND, 9.9%). Compared with Q3 2024, it opened 7 new positions, sold out of 3, added to 10 and reduced 7. The biggest buy was a new position in Blueprint Medicines (BPMC) and the biggest sale United Therapeutics (UTHR, shares −3%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001633313
- Portfolio Value
- $7.1B (Q4 2024)
- SEC Filing
- 0001104659-25-013529 ↗ filed Feb 14, 2025
Holdings Value
Holdings 39 stocks · $7.1B
| UTHR United Therapeutics Corp. | 13.78% | 2,760,300 | $973.9M | Reduce -3.5% |
| ARGX Argenx SE - ADR | 10.77% | 1,238,467 | $761.7M | No change |
| ASND Ascendis Pharma A/S | 9.94% | 5,103,055 | $702.5M | Add +2.3% |
| MDGL Madrigal Pharmaceuticals Inc. | 8.86% | 2,029,000 | $626.1M | No change |
| KRYS Krystal Biotech Inc. | 5.83% | 2,628,822 | $411.8M | Add +0.3% |
| APLS Apellis Pharmaceuticals Inc. | 5.52% | 12,222,222 | $390.0M | Add +10.0% |
| SRPT Sarepta Therapeutics Inc. | 4.40% | 2,555,555 | $310.7M | No change |
| ITCI Intra-Cellular Therapies Inc. | 3.60% | 3,050,000 | $254.7M | No change |
| VERA Vera Therapeutics Inc. | 3.36% | 5,610,000 | $237.2M | Add +30.2% |
| XENE Xenon Pharmaceuticals Inc. | 3.14% | 5,666,666 | $222.1M | No change |
| FOLD Amicus Therapeutics Inc. | 3.09% | 23,175,000 | $218.3M | No change |
| RNAM Avidity Biosciences Inc. | 3.08% | 7,500,000 | $218.1M | Add +9.1% |
| ARWR Arrowhead Pharmaceuticals Inc. | 2.95% | 11,111,111 | $208.9M | Add +25.0% |
| KYMR Kymera Therapeutics Inc. | 2.93% | 5,150,000 | $207.2M | Add +14.4% |
| MLTX Moonlake Immunotherapeutics | 2.12% | 2,770,100 | $150.0M | No change |
| SLNO Soleno Therapeutics Inc. | 1.61% | 2,525,000 | $113.5M | Add +15.8% |
| BPMC Blueprint Medicines Corp. | 1.46% | 1,185,000 | $103.4M | New |
| PCVX Vaxcyte Inc. | 1.36% | 1,175,000 | $96.2M | No change |
| BMRN Biomarin Pharmaceutical Inc. | 1.36% | 1,462,500 | $96.1M | Reduce -28.2% |
| MRUS Merus NV | 1.26% | 2,125,000 | $89.4M | Add +56.8% |
| BCRX Biocryst Pharmaceuticals Inc. | 1.26% | 11,865,000 | $89.2M | No change |
| ALKS Alkermes PLC | 1.00% | 2,450,000 | $70.5M | New |
| OCUL Ocular Therapeutix Inc. | 0.97% | 8,060,000 | $68.8M | No change |
| MNKD Mannkind Corp. | 0.80% | 8,750,000 | $56.3M | No change |
| TRML Tourmaline Bio Inc. | 0.64% | 2,222,222 | $45.1M | No change |
| QURE Uniqure NV | 0.54% | 2,175,000 | $38.4M | New |
| RARE Ultragenyx Pharmaceutical Inc. | 0.49% | 830,000 | $34.9M | No change |
| TSHA Taysha Gene Therapies Inc. | 0.49% | 19,999,999 | $34.6M | Add +7.2% |
| ETNB 89BIO Inc. | 0.45% | 4,100,000 | $32.1M | New |
| GLUE Monte Rosa Therapeutics Inc. | 0.43% | 4,345,000 | $30.2M | Reduce -25.0% |
| SNDX Syndax Pharmaceuticals Inc. | 0.43% | 2,275,000 | $30.1M | Reduce -41.5% |
| IOVA Iovance Biotherapeutics Inc. | 0.37% | 3,500,000 | $25.9M | Reduce -17.4% |
| SEPN Septerna Inc. | 0.36% | 1,110,000 | $25.4M | New |
| AUTL Autolus Therapeutics PLC | 0.33% | 9,910,642 | $23.3M | Reduce -19.7% |
| CGON CG Oncology Inc. | 0.28% | 700,000 | $20.1M | No change |
| KURA Kura Oncology Inc. | 0.28% | 2,250,000 | $19.6M | Reduce -36.5% |
| RCKT Rocket Pharmaceuticals Inc. | 0.21% | 1,200,000 | $15.1M | New |
| OLMA Olema Pharmaceuticals Inc. | 0.14% | 1,651,982 | $9.6M | New |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 0.13% | 2,849,402 | $9.0M | No change |
Portfolio Sells Q3 2024 → Q4 2024
| UTHR United Therapeutics Corp. | Reduce -3.5% | 13.78% | −1.16 |
| KURA Kura Oncology Inc. | Reduce -36.5% | 0.28% | −0.73 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -28.2% | 1.36% | −0.73 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -41.5% | 0.43% | −0.67 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −0.34 |
| AUTL Autolus Therapeutics PLC | Reduce -19.7% | 0.33% | −0.32 |
| SYRE Spyre Therapeutics Inc. | Sold out | 0.00% | −0.26 |
| IOVA Iovance Biotherapeutics Inc. | Reduce -17.4% | 0.37% | −0.21 |
| GLUE Monte Rosa Therapeutics Inc. | Reduce -25.0% | 0.43% | −0.02 |
| NGNE Neurogene Inc. | Sold out | 0.00% | −0.01 |
Portfolio Buys Q3 2024 → Q4 2024
| BPMC Blueprint Medicines Corp. | New | 1.46% | +1.46 |
| ALKS Alkermes PLC | New | 1.00% | +1.00 |
| APLS Apellis Pharmaceuticals Inc. | Add +10.0% | 5.52% | +0.84 |
| VERA Vera Therapeutics Inc. | Add +30.2% | 3.36% | +0.58 |
| QURE Uniqure NV | New | 0.54% | +0.54 |
| ETNB 89BIO Inc. | New | 0.45% | +0.45 |
| ARWR Arrowhead Pharmaceuticals Inc. | Add +25.0% | 2.95% | +0.44 |
| SEPN Septerna Inc. | New | 0.36% | +0.36 |
| MRUS Merus NV | Add +56.8% | 1.26% | +0.28 |
| RCKT Rocket Pharmaceuticals Inc. | New | 0.21% | +0.21 |
| OLMA Olema Pharmaceuticals Inc. | New | 0.14% | +0.14 |
| SLNO Soleno Therapeutics Inc. | Add +15.8% | 1.61% | −0.00 |
| TSHA Taysha Gene Therapies Inc. | Add +7.2% | 0.49% | −0.06 |
| KYMR Kymera Therapeutics Inc. | Add +14.4% | 2.93% | −0.18 |
| ASND Ascendis Pharma A/S | Add +2.3% | 9.94% | −0.92 |
| KRYS Krystal Biotech Inc. | Add +0.3% | 5.83% | −1.14 |
| RNAM Avidity Biosciences Inc. | Add +9.1% | 3.08% | −1.52 |
Options Activity Q3 2024 → Q4 2024
| INSMED INC | put | Sold out | 50,000 | $125Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $11.1B | UTHR, ASND, KRYS, MDGL, ARGX |
| Q1 2026 | 30 | $10.2B | UTHR, ASND, MDGL, KRYS, ARGX |
| Q4 2025Amended | 33 | $10.2B | UTHR, ASND, MDGL, ARGX, KRYS |
| Q3 2025 | 30 | $7.7B | ASND, UTHR, MDGL, ARGX, KRYS |
| Q2 2025 | 30 | $5.7B | ASND, UTHR, ARGX, MDGL, KRYS |
| Q1 2025 | 33 | $6.4B | UTHR, ASND, ARGX, MDGL, KRYS |
| Q4 2024 | 39 | $7.1B | UTHR, ARGX, ASND, MDGL, KRYS |
| Q3 2024 | 35 | $6.9B | UTHR, ASND, ARGX, KRYS, MDGL |
| Q2 2024 | 41 | $7.5B | UTHR, MDGL, ASND, ARGX, SRPT |
| Q1 2024 | 46 | $8.6B | UTHR, APLS, ASND, SRPT, MDGL |